The long term goal of this study is to prevent breast cancer progression by vaccination. New or over-expressed antigenic peptides presented by class I MMC are candidate tumor antigens. Peptide vaccination will be successful in preventing tumorigenesis if a panel of immunogenic peptides with overlapping expression by the majority of breast cancer cells are administered in a form which induces potent in vivo CTL response. The efficacy of tumor peptide vaccines will be tested in a mouse mammary tumor progression system with defined preneoplastic lesions. A fusion protein will be generated which contains H-2 Kd covalently linked to mouse mammary tumor virus (MMTV) peptide E474 expressed by tumor cells arising from BALB/c D2 preneoplastic hyperplastic alveolar nodule. The peptide in this fusion protein is not released from the complex and does not have to compete with natural peptides for MHC presentation. This stable and homogeneous presentation of tumor antigens in the peptide/MHC complex is expected to induce CTL with greatly enhanced frequency.
Specific Aim l is to test the induction of anti-tumor cytolytic T lymphocytes by fusion proteins which contain immunogenic peptides covalently linked to H2Kd. Immunization of healthy individuals carrying preneoplastic lesions is not without risk. The form and route of vaccination, the efficacy of tumor inhibition, the potential of inducing or selecting for nonimmunogenic tumor variants and the possible induction of autoimmunity must be evaluated in the truly syngeneic preneoplasia --> tumor progression system.
Specific Aim 2 is to test the effect of MMTV peptide vaccination on mammary tumor progression. The tremendous potential of tumor peptide vaccination is in contrast to the paucity of known human breast cancer associated antigens. Therefore, novel antigenic molecules will be identified from overexpressed mRNA by differential display using preneoplastic and neoplastic cells derived from the human breast epithelial cell line MCF-l0.
Specific aim 3 is to identify novel breast cancer associated antigens in preneoplastic and neoplastic cells derived from a human breast epithelial cell line MCF-l0. With the establishment of a breast cancer peptide panel, human breast cancer vaccines can be generated following the format established with mouse mammary tumor vaccines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA057831-06
Application #
2429757
Study Section
Special Emphasis Panel (ZRG5-ALY (02))
Project Start
1992-08-01
Project End
1999-05-31
Budget Start
1997-06-01
Budget End
1998-05-31
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Detroit
State
MI
Country
United States
Zip Code
48202
Wei, W Z; Shi, W P; Galy, A et al. (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748-54
Wei, W Z; Pauley, R; Lichlyter, D et al. (1998) Neoplastic progression of breast epithelial cells--a molecular analysis. Br J Cancer 78:198-204
Wei, W Z; Miller, B; Gutierrez, R M (1997) Inhibition of tumor growth by peptide specific cytotoxic T lymphocytes in a three-dimensional collagen matrix. J Immunol Methods 200:47-54
Wei, W Z; Heppner, G H (1996) Breast cancer immunology. Cancer Treat Res 83:395-410
Wei, W Z; Gill, R F; Jones, R F et al. (1996) Induction of cytotoxic T lymphocytes to murine mammary tumor cells with a Kd-restricted immunogenic peptide. Int J Cancer 66:659-63
Gill, R F; Abastado, J P; Wei, W Z (1994) Systematic identification of H-2 Kd binding peptides and induction of peptide specific CTL. J Immunol Methods 176:245-53
Wang, H; Gill, R F; Lichlyter, D et al. (1994) Deletion of CD4+ T cells and thymocytes by apoptosis in mouse mammary tumor virus (C4)-infected V beta 2 transgenic mice. Eur J Immunol 24:2950-6
Wei, W Z; Gill, R F; Wang, H (1993) Mouse mammary tumor virus associated antigens and superantigens--immuno-molecular correlates of neoplastic progression. Semin Cancer Biol 4:205-13